Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 40 of the 46 references it cites were found in a registry or an index; 3 of the 20 sources its claims cite were checked for support.

Inhibition of Human Cytochrome P450 Enzymes by Bacopa monnieri Standardized Extract and Constituents

Open access
Ramasamy, Seetha, Kiew, Lik, Chung, Lip · 2014 · Molecules

Abstract

Bacopa monnieri and the constituents of this plant, especially bacosides, possess various neuropharmacological properties. Like drugs, some herbal extracts and the constituents of their extracts alter cytochrome P450 (CYP) enzymes, causing potential herb-drug interactions. The effects of Bacopa monnieri standardized extract and the bacosides from the extract on five major CYP isoforms in vitro were analyzed using a luminescent CYP recombinant human enzyme assay. B. monnieri extract exhibited non-competitive inhibition of CYP2C19 (IC50/Ki = 23.67/9.5 µg/mL), CYP2C9 (36.49/12.5 µg/mL), CYP1A2 (52.20/25.1 µg/mL); competitive inhibition of CYP3A4 (83.95/14.5 µg/mL) and weak inhibition of CYP2D6 (IC50 = 2061.50 µg/mL). However, the bacosides showed negligible inhibition of the same isoforms. B. monnieri, which is orally administered, has a higher concentration in the gut than the liver; therefore, this herb could exhibit stronger inhibition of intestinal CYPs than hepatic CYPs. At an estimated gut concentration of 600 µg/mL (based on a daily dosage of 300 mg/day), B. monnieri reduced the catalytic activities of CYP3A4, CYP2C9 and CYP2C19 to less than 10% compared to the total activity (without inhibitor = 100%). These findings suggest that B. monnieri extract could contribute to herb-drug interactions when orally co-administered with drugs metabolized by CYP1A2, CYP3A4, CYP2C9 and CYP2C19.

Overview

CoChat Summary

TL;DR

Bacopa monnieri standardized extract inhibited several human CYP enzymes in vitro, most potently CYP2C19, while its bacoside constituents showed negligible inhibition. The authors suggest possible pre-systemic herb-drug interactions, especially via intestinal CYP3A4, CYP2C9, and CYP2C19 at estimated gut concentrations.

Key findings

  • B. monnieri extract showed moderate inhibition of CYP2C19 (IC50/Ki = 23.67/9.5 µg/mL), CYP2C9 (36.49/12.5 µg/mL), CYP1A2 (52.20/25.1 µg/mL), and CYP3A4 (83.95/14.5 µg/mL), with weak inhibition of CYP2D6 (IC50 = 2061.50 µg/mL).
  • Inhibition modes were non-competitive for CYP2C19, CYP2C9, and CYP1A2, and competitive for CYP3A4.
  • Bacoside A, bacoside A3, bacopaside II, bacopaside X, bacopasaponin C, and bacopaside I showed negligible inhibition of all five CYP isoforms at concentrations up to 100 µM.
  • At an estimated gut concentration of 600 µg/mL based on 300 mg/day and 500 mL intestinal volume, B. monnieri extract reduced CYP3A4, CYP2C9, and CYP2C19 activities to 4.1%, 4.9%, and 7.9% of total activity, respectively.

Methods

  • In vitro luminescent CYP recombinant human enzyme assay (P450-Glo™) using CYP1A2, CYP3A4, CYP2C9, CYP2C19, and CYP2D6.
  • B. monnieri extract was tested at 0.01–1000 µg/mL; bacosides and positive controls at 0.01–100 µM; all dissolved in DMSO with organic solvent kept below 0.25% (v/v).
  • IC50 values were calculated by non-linear regression; Ki values and inhibition modes were determined using Lineweaver-Burk plots and secondary plots of slopes versus extract concentration.

Limitations

  • The paper states that the compounds responsible for CYP inhibition by B. monnieri extract remain unknown and require further work.
  • The paper states that further in vivo investigation of drug-herb interactions between B. monnieri extracts and relevant drugs may be important.
  • Evident from the text: findings are from in vitro recombinant enzyme assays, and the estimated gut concentration and projected intestinal CYP activity are theoretical, based on a daily dose of 300 mg/day and an assumed 500 mL intestinal volume, without clinical confirmation.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/molecules19022588

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Structures of B. monnieri constituents, (A) bacoside A3; (B) bacopaside II; (C) bacopaside X; (D) bacopasaponin C and (E) bacopaside I. Bacoside A is a mixture of components A, B, C and D. These bacosides are dammarane-type triterpenoid saponins that have three sugar chains linked to a nonpolar triterpene aglycone skeleton.
Figure 1 Structures of B. monnieri constituents, (A) bacoside A3; (B) bacopaside II; (C) bacopaside X; (D) bacopasaponin C and (E) bacopaside I. Bacoside A is a mixture of components A, B, C and D. These bacosides are dammarane-type triterpenoid saponins that have three sugar chains linked to a nonpolar triterpene aglycone skeleton.CC BY · PubMed Central
Figure 2 B. monnieri extract showed strongest inhibitory effects towards CYP2C19 (A, IC50 = 23.67 µg/mL) followed by CYP2C9 (B, 36.49 µg/mL), CYP1A2 (C, 52.20 µg/mL), CYP3A4 (D, 83.95 µg/mL) and CYP2D6 (E, IC50 = 2061.50 µg/mL). Each point represents the average of triplicate determinations.
Figure 2 B. monnieri extract showed strongest inhibitory effects towards CYP2C19 (A, IC50 = 23.67 µg/mL) followed by CYP2C9 (B, 36.49 µg/mL), CYP1A2 (C, 52.20 µg/mL), CYP3A4 (D, 83.95 µg/mL) and CYP2D6 (E, IC50 = 2061.50 µg/mL). Each point represents the average of triplicate determinations.CC BY · PubMed Central
Figure 3 B. monnieri extract non-competitively inhibited CYP1A2, CYP2C9 and CYP2C19 activity and competitively inhibited CYP3A4 activity, as demonstrated by Lineweaver-Burk plots (A) CYP1A2; (B) CYP3A4; (C) CYP2C9 and (D) CYP2C19. The mode of inhibition was determined by incubating different concentrations of B. monnieri extract with increasing concentrations of substrates. Each point represents the average of duplicate measurements.
Figure 3 B. monnieri extract non-competitively inhibited CYP1A2, CYP2C9 and CYP2C19 activity and competitively inhibited CYP3A4 activity, as demonstrated by Lineweaver-Burk plots (A) CYP1A2; (B) CYP3A4; (C) CYP2C9 and (D) CYP2C19. The mode of inhibition was determined by incubating different concentrations of B. monnieri extract with increasing concentrations of substrates. Each point represents the average of duplicate measurements.CC BY · PubMed Central
Figure 4 Ki values of B. monnieri extract for (A) CYP1A2; (B) CYP3A4; (C) CYP2C9 and (D) CYP2C19. Ki values were determined from secondary plots of CYP activity using the slopes of primary Lineweaver–Burk plot versus concentrations of B. monnieri extract. Kinetic assays were carried out in the same conditions described in Figure 3. B. monnieri Ki values for CYP1A2, CYP3A4, CYP2C9 and CYP2C19 are of 25.1, 14.5, 12.5, and 9.5 μg/mL, respectively. Each point represents the average of duplicate measurements.
Figure 4 Ki values of B. monnieri extract for (A) CYP1A2; (B) CYP3A4; (C) CYP2C9 and (D) CYP2C19. Ki values were determined from secondary plots of CYP activity using the slopes of primary Lineweaver–Burk plot versus concentrations of B. monnieri extract. Kinetic assays were carried out in the same conditions described in Figure 3. B. monnieri Ki values for CYP1A2, CYP3A4, CYP2C9 and CYP2C19 are of 25.1, 14.5, 12.5, and 9.5 μg/mL, respectively. Each point represents the average of duplicate measurements.CC BY · PubMed Central

Verification

Claims the paper makes

3 Valid · 0 Not valid · 9 Not checked · 23 Own results and interpretations

6 more claims

Create a free account to see all 35 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 9
  • It may state two separate claims as one. 14
  • The quote only partly states this claim. 7

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 46 references

Research works printed but not linked: 2

  1. Tyagi, 2010, Herb-drug interactions: Emerging threat and their management, Bot. Res. Int., 3, 1
  2. Gunaratna, 2009, Drug metabolism & pharmacokinetics in drug discovery: A primer for bioanalytical chemists, part I, Curr. Sep., 19, 17

Cited by

See all 47

Metadata

Authors
Ramasamy, S., Kiew, L., & Chung, L.
Affiliations
University of Malaya (MY)
Corresponding author
Chung, Lip
Venue
Molecules
Publisher
MDPI AG
Published
2014-02-24
Volume
19
Issue
2
Pages
2588-2601
ISSN
1420-3049 (ISSN-L)
OpenAlex
W1977728948
Cited by
47
References
46
Citations by year
2026: 4 · 2025: 3 · 2024: 2 · 2023: 3 · 2022: 5 · 2021: 2 · 2020: 5 · 2019: 6 · 2018: 1 · 2017: 2 · 2016: 5 · 2015: 6 · 2014: 3
FWCI
3.59
Type
journal article
Language
en
Open access
Locations
  • Molecules (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Universiti Malaya
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Health Sciences › Medicine › Complementary and alternative medicine › Complementary and Alternative Medicine Studies
  • Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plants and Neuroprotection
Keywords
Bacopa monnieri, bacosides, cytochrome P450 inhibition, herb-drug interactions, CYP3A4, CYP2C19, CYP2C9, CYP1A2, CYP2D6, standardized herbal extract, intestinal drug metabolism
MeSH terms
Aryl Hydrocarbon Hydroxylases, Cytochrome P-450 Enzyme System, Humans, Inactivation, Metabolic, Microsomes, Liver, Plant Extracts, Saponins, Triterpenes, Cytochrome P-450 CYP1A2, Cytochrome P-450 CYP2D6, Bacopa, Herb-Drug Interactions, Cytochrome P-450 CYP3A, Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP2C19

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inhibition of Human Cytochrome P450 Enzymes by Bacopa monnieri Standardized Extract and Constituents. https://app.cochat.ai/papers/10.3390/molecules19022588
The paper
Ramasamy, S., Kiew, L., & Chung, L. (2014). Inhibition of Human Cytochrome P450 Enzymes by Bacopa monnieri Standardized Extract and Constituents. Molecules. https://doi.org/10.3390/molecules19022588

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.